A Phase 3, Randomized, Parallel-group, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With Coronavirus Disease 2019 (COVID-19) Not Requiring Supplemental Oxygen
Latest Information Update: 27 Jul 2022
At a glance
- Drugs CT P63 and CT P66 antibody cocktail-Celltrion (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
Most Recent Events
- 21 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment on sponsor's decision.
- 14 Feb 2022 New trial record